Should I buy or sell Assembly Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares. View ASMB analyst ratings or view top-rated stocks .

How have ASMB shares performed in 2024?

Assembly Biosciences' stock was trading at $9.8412 at the beginning of 2024. Since then, ASMB stock has increased by 35.5% and is now trading at $13.33. View the best growth stocks for 2024 here .

Are investors shorting Assembly Biosciences?

Assembly Biosciences saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 42,600 shares, a drop of 29.2% from the March 15th total of 60,200 shares. Based on an average trading volume of 29,900 shares, the short-interest ratio is presently 1.4 days. Approximately 1.2% of the company's shares are sold short. View Assembly Biosciences' Short Interest .

When is Assembly Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ASMB earnings forecast .

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) announced its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($4.92) earnings per share for the quarter, topping analysts' consensus estimates of ($6.84) by $1.92. The biopharmaceutical company had revenue of $6.25 million for the quarter.

When did Assembly Biosciences' stock split?

Shares of Assembly Biosciences reverse split on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com . John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend.

What other stocks do shareholders of Assembly Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI) , Exelixis (EXEL) , TG Therapeutics (TGTX) , Arbutus Biopharma (ABUS) , AVEO Pharmaceuticals (AVEO) , Sorrento Therapeutics (SRNE) , AbbVie (ABBV) , BioCryst Pharmaceuticals (BCRX) , Gilead Sciences (GILD) and Blueprint Medicines (BPMC) .

How do I buy shares of Assembly Biosciences?

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ASMB

Assembly Biosciences (ASMB) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ASMB Stock Alerts

$13.33

+0.41 (+3.17%)

(As of 04/18/2024 ET)

Compare

Today's Range: $12.40
▼
$13.33
50-Day Range: $11.11
▼
$15.06
52-Week Range: $7.69
▼
$20.04

Volume: 16,710 shs
Average Volume: 28,133 shs
Market Capitalization: $73.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Assembly Biosciences alerts:

Assembly Biosciences MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.17% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.71
Upright™ Environmental Score
News Sentiment: 0.08
Based on 18 Articles This Week
Insider Trading: Selling Shares
$26,924 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($12.65) to ($13.45) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.06 out of 5 stars

Medical Sector

778th out of 918 stocks

Pharmaceutical Preparations Industry

339th out of 402 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Assembly Biosciences.

5.0

Short Interest

Percentage of Shares Shorted
1.17% of the float of Assembly Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Assembly Biosciences has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Assembly Biosciences has recently decreased by 29.24%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Assembly Biosciences does not currently pay a dividend.
Dividend Growth
Assembly Biosciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Assembly Biosciences has received a 74.27% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for infectious diseases", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Assembly Biosciences is -0.71.

1.7

News and Social Media Coverage

News Sentiment
Assembly Biosciences has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 18 news articles for Assembly Biosciences this week, compared to 23 articles on an average week.
MarketBeat Follows
4 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Assembly Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,924.00 in company stock.
Percentage Held by Insiders
Only 4.10% of the stock of Assembly Biosciences is held by insiders.
Percentage Held by Institutions
Only 19.92% of the stock of Assembly Biosciences is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Assembly Biosciences are expected to decrease in the coming year, from ($12.65) to ($13.45) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Assembly Biosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Assembly Biosciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Assembly Biosciences has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Assembly Biosciences Stock (NASDAQ:ASMB)

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

ASMB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ASMB Stock News Headlines

April 3, 2024 | insidertrades.com

Assembly Biosciences, Inc. (NASDAQ:ASMB) Director John G. Mchutchison Sells 1,206 Shares

April 18, 2024 | msn.com

Assembly elections 2024: Full List of 92 Arunachal Pradesh, Sikkim constituencies going to polls on April 19

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 18, 2024 | yahoo.com

New Jersey Assembly Approves Bill to Help School Districts Facing State Aid Cuts

April 18, 2024 | news.yahoo.com

'Maryland's win'? Gov. Moore assesses record of 2024 General Assembly session

April 18, 2024 | news.yahoo.com

Bill to ban plastic six-pack rings introduced to General Assembly

April 17, 2024 | msn.com

General Assembly back in session after Youngkin amendments

April 17, 2024 | msn.com

Racist opposition to this Assembly bill proves hate still thrives in liberal California | Opinion

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 17, 2024 | msn.com

Bill to help school districts with state aid cuts passes state Assembly

April 17, 2024 | news.yahoo.com

Budget, skill games topics for General Assembly veto session

April 17, 2024 | msn.com

Kuwait National Assembly ‘Opener’ Set for April 21

April 16, 2024 | msn.com

Kaduna Assembly probes El-Rufai’s loans, directs committee to summon ex-gov

April 16, 2024 | msn.com

Odisha Assembly Polls: BJP Releases Names Of 21 Candidates, Dilip Ray To Contest From Rourkela

April 15, 2024 | msn.com

Tennessee General Assembly passes 'Jillian's Law' in honor of slain Belmont student

April 15, 2024 | msn.com

Rep. Edming to not seek re-election to State Assembly

April 15, 2024 | msn.com

Kebbi Assembly suspends member for alleged unguarded utterances

April 13, 2024 | msn.com

AIMIM Supports AIADMK In TN For LS Polls, Pact To Continue For Assembly Elections Too

April 13, 2024 | msn.com

California Assembly Introduces Legislation to Combat Retail Theft

April 12, 2024 | usatoday.com

Kyle Kehoe announces Democratic bid for Fox Crossing, Winneconne area Assembly District 55

April 12, 2024 | msn.com

3 local primaries for General Assembly seats. Some candidates share their views on issues

April 11, 2024 | msn.com

23 Candidates In Arunachal Assembly Polls Have Criminal Cases

April 11, 2024 | msn.com

Rep. Rozar will run for re-election in 86th Assembly District

April 11, 2024 | msn.com

An all-Republican local Assembly race was already contentious. Now it’s prompted a GOP leadership shake-up.

April 10, 2024 | msn.com

Three independent MLAs move Himachal HC against Assembly Speaker for not accepting their resignations

April 9, 2024 | msn.com

NY Assembly Speaker Carl Heastie faces GOP challenger fed up with crime, bail policies

April 9, 2024 | msn.com

One candidate, two races: Court says Vince Fong can run for both Congress and CA Assembly

See More Headlines

Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:ASMB
CUSIP: 92282210
CIK: 1426800
Web: www.assemblybio.com
Phone: (833) 509-4583
Fax: 646-706-5101
Employees: 65
Year Founded: 2005

Profitability

EPS (Most Recent Fiscal Year): ($17.0468)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-61,230,000.00
Net Margins: N/A
Pretax Margin: -854.32%
Return on Equity: -117.69%
Return on Assets: -72.43%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.41
Quick Ratio: 3.41

Sales & Book Value

Annual Sales: $7.16 million
Price / Sales: 9.64
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.50 per share
Price / Book: 1.68

Miscellaneous

Outstanding Shares: 5,480,000
Free Float: 5,258,000
Market Cap: $69.05 million
Optionable: Optionable
Beta: 0.57

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Jason A. Okazaki (Age 48)
CEO, President & Director
Comp: $869.28k
Dr. William E. Delaney IV (Age 52)
Ph.D., Chief Scientific Officer
Comp: $664.4k
Dr. Uri A. Lopatin M.D. (Age 52)
Co-Founder and Clinical & Scientific Advisor
Comp: $608.55k
Dr. Adam Zlotnick
Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
Jeanette M Bjorkquist
Executive Director of Accounting & Treasury
Shannon Ryan
Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management
Ms. Jennifer A. Troia MHROD
SHRM-SCP, SPHR, Chief Human Resources Officer
Dr. Nicole S. White Ph.D.
Chief Manufacturing Officer
Dr. Anuj Gaggar M.D.
Ph.D., Chief Medical Officer
Mr. Thomas E. Rollins (Age 68)
Executive Officer
Comp: $472.55k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ASMB Stock Analysis - Frequently Asked Questions

Should I buy or sell Assembly Biosciences stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares.
View ASMB analyst ratings or view top-rated stocks.
How have ASMB shares performed in 2024?: Assembly Biosciences' stock was trading at $9.8412 at the beginning of 2024. Since then, ASMB stock has increased by 35.5% and is now trading at $13.33.
View the best growth stocks for 2024 here.
Are investors shorting Assembly Biosciences?: Assembly Biosciences saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 42,600 shares, a drop of 29.2% from the March 15th total of 60,200 shares. Based on an average trading volume of 29,900 shares, the short-interest ratio is presently 1.4 days. Approximately 1.2% of the company's shares are sold short.
View Assembly Biosciences' Short Interest.
When is Assembly Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our ASMB earnings forecast.
How were Assembly Biosciences' earnings last quarter?: Assembly Biosciences, Inc. (NASDAQ:ASMB) announced its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($4.92) earnings per share for the quarter, topping analysts' consensus estimates of ($6.84) by $1.92. The biopharmaceutical company had revenue of $6.25 million for the quarter.

When did Assembly Biosciences' stock split?: Shares of Assembly Biosciences reverse split on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What is John McHutchison's approval rating as Assembly Biosciences' CEO?: 8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend.
What other stocks do shareholders of Assembly Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC).
How do I buy shares of Assembly Biosciences?: Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASMB) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Assembly Biosciences (ASMB) Stock Price, News & Analysis

Assembly Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Assembly Biosciences Stock (NASDAQ:ASMB)

ASMB Stock Price History

ASMB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ASMB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™